Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine

KOJI NUMATA, SOICHIRO MORINAGA, YUSUKE KATAYAMA, SHO SAWAZAKI, MASAKATSU NUMATA, TENI GODAI, AKIO HIGUCHI, MANABU SHIOZAWA, YASUSHI RINO, MUNETAKA MASUDA and MAKOTO AKAIKE
Anticancer Research May 2016, 36 (5) 2467-2474;
KOJI NUMATA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: koji-numata@hotmail.co.jp
SOICHIRO MORINAGA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUSUKE KATAYAMA
2Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHO SAWAZAKI
2Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAKATSU NUMATA
2Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TENI GODAI
3Department of Surgery, Fujisawa Shonandai Hospital, Fujisawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIO HIGUCHI
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MANABU SHIOZAWA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUSHI RINO
2Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MUNETAKA MASUDA
2Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAKOTO AKAIKE
4Department of General Medicine, Chigasaki Chuo Hospital, Chigasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 36 no. 5 2467-2474
PubMed 
27127159

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received February 22, 2016
  • Revision received March 30, 2016
  • Accepted April 4, 2016
  • Published online April 28, 2016.

Copyright & Usage 
Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. KOJI NUMATA1⇑,
  2. SOICHIRO MORINAGA1,
  3. YUSUKE KATAYAMA2,
  4. SHO SAWAZAKI2,
  5. MASAKATSU NUMATA2,
  6. TENI GODAI3,
  7. AKIO HIGUCHI1,
  8. MANABU SHIOZAWA1,
  9. YASUSHI RINO2,
  10. MUNETAKA MASUDA2 and
  11. MAKOTO AKAIKE4
  1. 1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan
  2. 2Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan
  3. 3Department of Surgery, Fujisawa Shonandai Hospital, Fujisawa, Japan
  4. 4Department of General Medicine, Chigasaki Chuo Hospital, Chigasaki, Japan
  1. Correspondence to: Koji Numata, MD, Department of Surgery, International University of Health and Welfare Atami Hospital, 13-1 Higashikaigan-cho, Atami, Shizuoka 413-0012, Japan. Tel: +81 557819171, Fax: +81 557836632, e-mail: koji-numata{at}hotmail.co.jp
View Full Text

Cited By...

  • 8 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 36 (5)
Anticancer Research
Vol. 36, Issue 5
May 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine
KOJI NUMATA, SOICHIRO MORINAGA, YUSUKE KATAYAMA, SHO SAWAZAKI, MASAKATSU NUMATA, TENI GODAI, AKIO HIGUCHI, MANABU SHIOZAWA, YASUSHI RINO, MUNETAKA MASUDA, MAKOTO AKAIKE
Anticancer Research May 2016, 36 (5) 2467-2474;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine
KOJI NUMATA, SOICHIRO MORINAGA, YUSUKE KATAYAMA, SHO SAWAZAKI, MASAKATSU NUMATA, TENI GODAI, AKIO HIGUCHI, MANABU SHIOZAWA, YASUSHI RINO, MUNETAKA MASUDA, MAKOTO AKAIKE
Anticancer Research May 2016, 36 (5) 2467-2474;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • Glasgow prognostic score
  • carbohydrate antigen 19-9
  • pancreatic cancer
  • early recurrence
  • gemcitabine monotherapy
  • curative surgery
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire